PE20011218A1 - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
PE20011218A1
PE20011218A1 PE2001000417A PE2001000417A PE20011218A1 PE 20011218 A1 PE20011218 A1 PE 20011218A1 PE 2001000417 A PE2001000417 A PE 2001000417A PE 2001000417 A PE2001000417 A PE 2001000417A PE 20011218 A1 PE20011218 A1 PE 20011218A1
Authority
PE
Peru
Prior art keywords
ryk
refers
disease
cardiovascular
amino acids
Prior art date
Application number
PE2001000417A
Other languages
English (en)
Spanish (es)
Inventor
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Steve Roczniak
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20011218A1 publication Critical patent/PE20011218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2001000417A 2000-05-10 2001-05-10 Metodo para regular la angiogenesis utilizando proteina ryk PE20011218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
PE20011218A1 true PE20011218A1 (es) 2002-02-01

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000417A PE20011218A1 (es) 2000-05-10 2001-05-10 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (enExample)
JP (1) JP2004527206A (enExample)
AR (1) AR028424A1 (enExample)
AU (1) AU2001261343A1 (enExample)
CA (1) CA2408349A1 (enExample)
CO (1) CO5300464A1 (enExample)
DO (1) DOP2001000164A (enExample)
EC (1) ECSP014068A (enExample)
GT (1) GT200100079A (enExample)
PE (1) PE20011218A1 (enExample)
SV (1) SV2002000442A (enExample)
UY (1) UY26696A1 (enExample)
WO (1) WO2001085789A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516608A (ja) * 2002-02-06 2005-06-09 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング エネルギー恒常性の調節に関与するキナーゼ
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶（ｒｙｋ）抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107472A (en) * 1992-05-11 2000-08-22 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
EP1084245B1 (en) * 1998-06-11 2006-03-29 AstraZeneca AB Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
SV2002000442A (es) 2002-07-03
CA2408349A1 (en) 2001-11-15
EP1287121A2 (en) 2003-03-05
AU2001261343A1 (en) 2001-11-20
GT200100079A (es) 2001-12-31
ECSP014068A (es) 2002-02-25
UY26696A1 (es) 2001-12-28
DOP2001000164A (es) 2002-05-15
WO2001085789A2 (en) 2001-11-15
AR028424A1 (es) 2003-05-07
JP2004527206A (ja) 2004-09-09
WO2001085789A3 (en) 2002-05-16
CO5300464A1 (es) 2003-07-31

Similar Documents

Publication Publication Date Title
AU772930B2 (en) Chimaeric proteins between members of TGF-beta superfamily
CR7584A (es) Nuevas proteinas de fusion con trombomodulina dirigidas contra factores tisulares como anticoagulantes
ES2115662T3 (es) Modificacion genetica de celulas endoteliales.
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
ES2146552B1 (es) Peptidos inhibidores de tgf/31
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CR20110556A (es) Proteinas de fusion rage y metodos de empleo
ES2123062T3 (es) Polipeptidos de transporte derivados de la proteina tat.
ATE202115T1 (de) Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis.
AR040226A1 (es) Productos parenterales antifungicos
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
ES2167311T3 (es) Bancos de peptidos modificados resistentes a proteasas.
PT835262E (pt) Metodo para o tratamento de osteopenia induzida por corticosteroides
BR9815142A (pt) "proteìna isolada e modificada; vesicula; método de geração de um complexo proteìco multivalente; de modificação de uma proteìna; de tratamento de um disturbio neurológico; de alteração do estado de crescimento de uma célula; complexo proteìco; polipeptideo de ouriço; polipeptideo de ouriço modificado; proteìna sintética recombinante e uso terapêutico da proteìna"
ES2063370T3 (es) Agentes mejorados para el control biologico de insectos y metodos de uso.
ES2055035T3 (es) Un proceso para la preparacion de un glicosido de antraciclina.
PE20011218A1 (es) Metodo para regular la angiogenesis utilizando proteina ryk
ES2545614T3 (es) Proteínas truncadas con nudo de cistina
Calì et al. CXCR4-mediated glutamate exocytosis from astrocytes
ES2176202T3 (es) Promotores eucarioticos sinteticos que contienen dos elementos inducibles.
BR0014183A (pt) Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
JP2005287515A (ja) 形態形成タンパク質を含むＴＧＦ−βスーパーファミリー変異体メンバー
Howell et al. Endothelial cell confluence regulates Weibel-Palade body formation
AR117707A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf

Legal Events

Date Code Title Description
FC Refusal